System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Interventional Recruiting Phase 4

NCT06792422 on ClinicalTrials.gov

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

Official title: Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection

  • Sponsor: Glostrup Hospital
  • Enrollment: 126 (Estimated)
  • Study start: 2025-01-01 (Estimated)
  • Primary completion: 2028-08-01 (Estimated)
  • Study completion: 2028-12-01 (Estimated)
  • Allocation: Randomized
  • InterventionModel: Parallel
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • PrimaryPurpose: Treatment

Brief Summary

The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram.

Researchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug).

Participants will:

* Take semaglutide or a placebo every day for 6 months.
* Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).

Conditions

  • Primary Open Angle Glaucoma (POAG)
  • Open-Angle Glaucoma
  • Glaucoma

Intervention / Treatment

  • Drug: Oral semaglutide
  • Drug: Placebo

Primary Outcome Measures

  • Photopic negative response of the electroretinogram after 6 months (From baseline to month 6.)
    Change in the inner retinal function assessed by mean change in the photopic negative response of the electroretinogram.

Countries

Denmark

Locations and Investigators